Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3382 Comments
771 Likes
1
Morrise
Loyal User
2 hours ago
My respect levels just skyrocketed.
👍 194
Reply
2
Lyndzi
Active Contributor
5 hours ago
I agree, but don’t ask me why.
👍 159
Reply
3
Annemargaret
Engaged Reader
1 day ago
I read this with full confidence and zero understanding.
👍 51
Reply
4
Flavil
Returning User
1 day ago
I’m not sure what I just agreed to.
👍 233
Reply
5
Xayvier
Expert Member
2 days ago
This feels like something important happened.
👍 74
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.